Drugs / gp100
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00003897 | May 1999 → Mar 2001 | cutaneous melanoma | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1 | NCT00003792 | Apr 1999 → Oct 2006 | cutaneous melanoma | Baylor Health Care System | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00019214 | Apr 1997 → Jul 2006 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00295958 | Dec 2005 → Jun 2006 | cutaneous melanoma | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 2 | NCT00006385 | Sep 2000 → Oct 2006 | cutaneous melanoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00006113 | Jun 1999 → May 2003 | cutaneous melanoma | University of Southern California | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00036816 | Feb 2002 → Feb 2003 | uveal melanoma | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00559026 Comparator | Sep 2004 → Sep 2006 | melanoma | Italian National Institute of Health | Completed | No outcome recorded |
| Phase 2 | NCT00960752 Comparator | May 2010 → Jul 2020 | melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp100 | “Patients included in the study were assigned to two treatment arms either receiving anti-tumor vaccination with Melan-A and gp100 analog peptides alone (arm 1) or in...” NCT00559026 ↗ |
| Modality | Vaccine | “Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma” NCT00003897 ↗ |
| Route | Intravenous | “vaccinations with dendritic cells pulsed with MART-1 and gp100 antigens, either intralymphatically every 4 weeks for 2 doses, or IV every 3 weeks for 4 doses” NCT00019214 ↗ |
| Route | Other | “vaccinations with dendritic cells pulsed with MART-1 and gp100 antigens, either intralymphatically every 4 weeks for 2 doses, or IV every 3 weeks for 4 doses” NCT00019214 ↗ |